ATE301459T1 - Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen - Google Patents

Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen

Info

Publication number
ATE301459T1
ATE301459T1 AT97944319T AT97944319T ATE301459T1 AT E301459 T1 ATE301459 T1 AT E301459T1 AT 97944319 T AT97944319 T AT 97944319T AT 97944319 T AT97944319 T AT 97944319T AT E301459 T1 ATE301459 T1 AT E301459T1
Authority
AT
Austria
Prior art keywords
norboronanedioles
norbornene
treatment
diseases
proliferative skin
Prior art date
Application number
AT97944319T
Other languages
English (en)
Inventor
David A Brown
Alexander A Khorlin
Krystyna Lesiak
Wu Yun Ren
Original Assignee
Applied Genetics Inc Dermatics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genetics Inc Dermatics filed Critical Applied Genetics Inc Dermatics
Application granted granted Critical
Publication of ATE301459T1 publication Critical patent/ATE301459T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
AT97944319T 1996-09-18 1997-09-18 Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen ATE301459T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2657796P 1996-09-18 1996-09-18
US3594797P 1997-01-21 1997-01-21
US3686397P 1997-02-04 1997-02-04
US4859797P 1997-06-04 1997-06-04
PCT/US1997/016642 WO1998011882A1 (en) 1996-09-18 1997-09-18 Pharmaceutical compositions and methods

Publications (1)

Publication Number Publication Date
ATE301459T1 true ATE301459T1 (de) 2005-08-15

Family

ID=27487517

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97944319T ATE301459T1 (de) 1996-09-18 1997-09-18 Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen

Country Status (9)

Country Link
US (2) US5990177A (de)
EP (1) EP0957903B1 (de)
AT (1) ATE301459T1 (de)
AU (1) AU740783B2 (de)
CA (1) CA2266496A1 (de)
DE (1) DE69733968T2 (de)
DK (1) DK0957903T3 (de)
ES (1) ES2245465T3 (de)
WO (1) WO1998011882A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214888B1 (en) 1996-09-18 2001-04-10 Applied Genetics Incorporated Dermatological compounds
DK0957903T3 (da) 1996-09-18 2005-11-21 Applied Genetics Inc Dermatics Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser
US6623724B2 (en) 1996-09-18 2003-09-23 Applied Genetics Incorporated Dermatics Dermatological compositions and methods
JP2001511151A (ja) * 1997-02-04 2001-08-07 ザ ジェネラル ホスピタル コーポレイション 表皮又は皮膚疾患部の処理方法と形質転換動物
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6267948B1 (en) 1998-04-06 2001-07-31 Applied Genetics Incorporated Dermatics Dermatological formulations and methods
JP2002518340A (ja) * 1998-06-15 2002-06-25 ニューロンズ・リミテッド チロシンヒドロキシラーゼの調整
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
US6359153B1 (en) * 1998-10-28 2002-03-19 Hyundai Electronics Industries Co., Ltd. Photoresist monomers and preparation thereof
WO2001068576A1 (en) * 2000-03-10 2001-09-20 Applied Genetics Incorporated Dermatics Dermatological compounds
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
DE10111050A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
US6682753B2 (en) * 2001-03-23 2004-01-27 Neuronz Limited Methods for promoting weight gain using GPE-related compounds
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
AU2002303856A1 (en) 2001-05-24 2002-12-03 Neuronz Limited Gpe analogs and peptidomimetics
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20040192638A1 (en) * 2001-07-02 2004-09-30 Oaks John A. Method and composition for prolonging the residence time of drugs in the gut
WO2003004096A2 (en) * 2001-07-02 2003-01-16 Wisconsin Alumni Research Foundation Method and composition for prolonging the residence time of drugs in the gut
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
FR2840530B1 (fr) * 2002-06-11 2004-12-24 Oreal Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
AU2004242507B2 (en) * 2002-06-12 2009-02-19 Piotr Chomczynski Method of treating rosacea
AU2003243603A1 (en) * 2002-06-13 2003-12-31 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
FR2856926B1 (fr) * 2003-07-02 2005-09-30 Centre Nat Rech Scient Utilisation des n-alkanols comme activateurs du canal cftr
US9433797B2 (en) 2003-12-05 2016-09-06 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurodegenerative conditions
US9415233B2 (en) 2003-12-05 2016-08-16 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurological pain
US9440089B2 (en) 2003-12-05 2016-09-13 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke
US10350428B2 (en) 2014-11-04 2019-07-16 Endonovo Therapetics, Inc. Method and apparatus for electromagnetic treatment of living systems
US9656096B2 (en) 2003-12-05 2017-05-23 Rio Grande Neurosciences, Inc. Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans
US8961385B2 (en) 2003-12-05 2015-02-24 Ivivi Health Sciences, Llc Devices and method for treatment of degenerative joint diseases with electromagnetic fields
WO2005102188A1 (en) 2004-04-19 2005-11-03 Ivivi Technologies, Inc. Electromagnetic treatment apparatus and method
EP1749017A2 (de) * 2004-05-27 2007-02-07 MIGENIX Corp. Verbindungen und verfahren für zytoprotektion
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
US9579298B2 (en) * 2004-12-02 2017-02-28 Piotr Chomczynski Antioxidant dietary supplement compositions and methods for maintaining healthy skin
FR2889808B1 (fr) 2005-08-17 2011-07-22 Oreal Utilisation de l'acide 8-hexadecene-1,16-dicarboxylique comme agent de soin destine a favoriser la cohesion de la couche cornee
US20090325911A1 (en) * 2005-10-21 2009-12-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Androgens for the Treatment of Parkinson's Disease
KR101111020B1 (ko) * 2006-07-04 2012-03-13 주식회사 알엔에스 신규한 사이클릭 화합물의 유도체 및 그의 용도
WO2008036383A1 (en) * 2006-09-20 2008-03-27 Ivivi Technologies, Inc. Electromagnetic apparatus for respiratory disease and method for using same
US20080250120A1 (en) * 2007-02-22 2008-10-09 Colin Kennedy Mick Method and apparatus for distributing a multimedia file to a public kiosk across a network
EP2848252A3 (de) * 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Aldose-Reduktase-Inhibitoren zur Behandlung von Uveitis
WO2009046322A2 (en) * 2007-10-03 2009-04-09 Florida Atlantic University Compositions and methods for treating neural anoxia and spreading depression
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
KR101050429B1 (ko) * 2009-03-18 2011-07-19 연세대학교 산학협력단 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
CN101797243B (zh) * 2010-03-23 2012-01-18 广东药学院 一种含有左旋多巴和冰片的组合物及其应用
RU2582339C2 (ru) 2010-05-27 2016-04-27 Таргасепт, Инк. Неконкурентные антагонисты никотиновых рецепторов
CA2813036A1 (en) 2010-10-01 2012-04-05 Ivivi Health Sciences, Llc Method and apparatus for electromagnetic treatment of head, cerebral and neural injury in animals and humans
ITMI20111260A1 (it) * 2011-07-06 2013-01-07 Carmelo Cutrupi Composizioni topiche per l'uso nella prevenzione e/o nel trattamento di dermatiti
US8343027B1 (en) 2012-01-30 2013-01-01 Ivivi Health Sciences, Llc Methods and devices for providing electromagnetic treatment in the presence of a metal-containing implant
US9907776B2 (en) * 2013-03-12 2018-03-06 Bio-Pharm Solutions, Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same
WO2015161063A1 (en) 2014-04-16 2015-10-22 Iviv Health Sciences, Llc A two-part pulsed electromagnetic field applicator for application of therapeutic energy
CN105693817B (zh) * 2014-11-27 2020-06-05 西北大学 一类三肽化合物及其制备方法与应用
WO2018089795A1 (en) 2016-11-10 2018-05-17 Qoravita LLC System and method for applying a low frequency magnetic field to biological tissues

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT279052B (de) 1968-08-08 1970-02-25 Dragoco Gerberding Co Gmbh Lichtschutzmittel
DE2350315C2 (de) * 1973-10-06 1984-01-12 Johnson & Johnson GmbH, 4000 Düsseldorf Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung
US3956361A (en) 1974-05-23 1976-05-11 Ciba-Geigy Corporation Hindered phenolic derivatives of norbornane thioalcohols
US4102995A (en) * 1976-05-13 1978-07-25 Westwood Pharmaceuticals Inc. Tar gel formulation
DE3025187A1 (de) * 1980-07-03 1982-02-11 Henkel KGaA, 4000 Düsseldorf Neue riechstoffe, deren herstellung sowie diese enthaltende riechstoffkompositionen
US4647585A (en) 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
SE462139B (sv) * 1986-02-04 1990-05-14 Sven Moberg Farmaceutisk komposition, innehaallande propylenglykol och karbamid, foer behandling av bl.a. nagelsvamp och seborroiskt eksem
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
DE3724691C2 (de) * 1987-07-25 1999-03-18 Konrad Minninger Pharmazeutisches Mittel zur lokalen Therapie von schuppenden Hautkrankheiten
US5700450A (en) * 1988-03-30 1997-12-23 The Trustees Of Boston University Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof
US5352440A (en) * 1988-03-30 1994-10-04 Trustees Of Boston University Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof
DE3925634A1 (de) * 1989-08-03 1991-02-07 Bayer Ag Stabilisatordispersionen
US5190978A (en) * 1989-09-29 1993-03-02 Dai-Ichi Kogyo Seiyaku Co. Ltd. Carcinostatic compositions and methods
JP3013540B2 (ja) 1990-09-18 2000-02-28 住友化学工業株式会社 害虫忌避剤
US5190798A (en) * 1992-01-09 1993-03-02 Gilbert Bloch Paper-plastic film, fiberglass-reinforced sealing tape
US5414019A (en) 1992-04-09 1995-05-09 Wisconsin Alumni Research Foundation Regression of mammalian carcinomas
US5587402A (en) 1992-04-09 1996-12-24 Wisconsin Alumni Research Foundation Regression of mammalian leukemia cell tumors
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5470577A (en) * 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
EP0643113B1 (de) * 1993-09-09 2001-11-28 E.I. Du Pont De Nemours And Company Wässrige Tintenzusammensetzung, die Mittel gegen das Einrollen von Papier enthält
US5434144A (en) * 1994-03-04 1995-07-18 The Procter & Gamble Company Methods of using cyclic polyanionic polyol derivatives for regulating skin wrinkles
US5626839A (en) * 1994-11-08 1997-05-06 Scales-Medeiros; Virginia Light responsive self-tanning products and methods for use
AU6544396A (en) * 1995-07-11 1997-02-10 Procter & Gamble Company, The Concentrated, water dispersible, stable, fabric softening compositions
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
AU2099397A (en) * 1996-02-21 1997-09-10 Stoa S.A. Cosmetic, dermopharmaceutical or veterinary compositions for disinfecting human or animal skin
WO1998055085A1 (en) * 1997-06-04 1998-12-10 Codon Pharmaceuticals, Inc. Pharmaceutical compositions and methods
DK0957903T3 (da) 1996-09-18 2005-11-21 Applied Genetics Inc Dermatics Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser
JP2001515026A (ja) * 1997-08-21 2001-09-18 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 加齢または日光により損傷した皮膚および／または皮膚萎縮の処置のための１７−α−エストラジオールの使用

Also Published As

Publication number Publication date
DK0957903T3 (da) 2005-11-21
EP0957903A1 (de) 1999-11-24
EP0957903A4 (de) 2002-10-09
AU740783B2 (en) 2001-11-15
WO1998011882A1 (en) 1998-03-26
DE69733968D1 (de) 2005-09-15
US5990177A (en) 1999-11-23
AU4584297A (en) 1998-04-14
DE69733968T2 (de) 2006-06-01
ES2245465T3 (es) 2006-01-01
US6294585B1 (en) 2001-09-25
CA2266496A1 (en) 1998-03-26
EP0957903B1 (de) 2005-08-10

Similar Documents

Publication Publication Date Title
ATE301459T1 (de) Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60144277D1 (de) Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
BG103575A (en) SUBSTITUTED NITROGENCONTAINING HETEROCYCLES AS p38 PROTEINKINASE INHIBIRORS
DE3860043D1 (de) Verwendung von biertreberextrakt zur herstellung von medizinischen und kosmetischen zubereitungen.
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
DE69737397D1 (de) Verwendung von mif-antagonisten zur krebstherapie
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
GR1002802B (el) Καλλυντικες συνθεσεις και συνθεσεις περιποιησεως του δερματος
NO994330L (no) Metode for behandling av en tumor
EP0214254A1 (de) Melatoninhaltige mittel sowie deren verwendungen.
DE69621243D1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
NO931413L (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DE69900774D1 (de) Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0957903

Country of ref document: EP

REN Ceased due to non-payment of the annual fee